BASEL, Switzerland and LONDON, UK and NEW YORK, NY, USA I December 03, 2024 I Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced its Phase 2 study failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis. The Phase 2 RESOLVE-Lung study (NCT05314517) evaluated the efficacy and safety of namilumab, an investigational anti-GM-CSF monoclonal antibody administered once-mont

— Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed by Topline Data from the Booster Dose Approximately Nine Months Later — — VAX-31 is Designed to Cover Approximately 94% of Invasive Pneumococcal Disease and Approximately 93% of Acute Otitis Media in U.S. Children Under Five — — VAX-31 Offers Potential to Protect Vulnerable Population by Providing Greater Coverage Against Both Currently Cir

SALT LAKE CITY, UT, USA I December 03, 2024 I Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. Recursion identified the novel regulatory role of RBM39 on CDK12 function using its AI-powered maps of biology. Recursion believes the modulation of RBM39

Agreement demonstrates the expanding leadership of Accord BioPharma and Intas in the biosimilar market RALEIGH, NC, USA I December 3, 2024 I Accord BioPharma , Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. (“Intas Pharmaceuticals”), focused on the development of oncology, immunology and critical care therapies, announced today that Intas Pharmaceuticals has signed an agreement to acquire the UDENYCA® (pegfilgrastim-cbqv) business from Coherus BioSciences, Inc. (“Coherus”). UDE

TORINO, Italy I December 03, 2024 I Resalis Therapeutics today announced the initiation of its first-in-human, Phase 1 study for RES-010, a non-coding RNA-based compound designed to provide a disease-modifying approach to obesity treatment. Preclinical studies have demonstrated that RES-010 reduces fat mass, preserves lean body mass, and enhances energy expenditure. By targeting fat reduction across various regions of the body, including visceral and hepatic stores, RES-010 has the potential to

– Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis’ Differentiated ADC Platform Technologies with Gilead’s Oncology Research and Development Expertise – – Agreement Provides Gilead with Exclusive Option to License the Resulting ADC Program for Further Development – FOSTER CITY, CA, USA & MUNICH, Germany I December 03, 2024 I Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license agreement to d

Services in the Pavilion for Child and Adolescent Health made possible through a partnership with San Manuel Band of Mission Indians and Loma Linda University Children's Hospital RANCHO MIRAGE, Calif., Dec. 3, 2024 /PRNewswire/ -- Today, the Barbara Sinatra Children's Center (BSCC) broke ground on a new wing of its facility to expand the Center's forensic medical services to patients ages 18 and under. The Pavilion for Child and Adolescent Health expansion project is expected to be complete in e

Hyundai Hope invests in new Diabetic Exam Room and Diabetic Group Medical Visits at the UCI Health Family Health Center in Santa Ana and Anaheim, California FOUNTAIN VALLEY, Calif., Dec. 3, 2024 /PRNewswire/ -- Hyundai Motor America announced a $50,000 donation to UCI Health to bolster its diabetes support services at the UCI Health Family Health Center in Santa Ana and Anaheim, California, the oldest Federally Qualified Health Centers (FQHC) in Orange County. The investment will help create a

TAMPA, Fla., Dec. 3, 2024 /PRNewswire/ -- Regener-Eyes LLC, the distributors of Regener-Eyes Professional Strength and Regener-Eyes LITE, recently launched their new preservative-free bottles with back flow prevention. The previous bottle design did not provide backflow prevention. After consulting with physicians and industry experts, Regener-Eyes developed and launched this improved bottle design. "We have listened to feedback from physicians and patients nationwide. Regener-Eyes is trusted by

WASHINGTON--( BUSINESS WIRE )--The ASH Research Collaborative (ASH RC), a non-profit organization established by the American Society of Hematology (ASH) to improve the lives of those affected by blood diseases, will present new data at the 66th ASH Annual Meeting and Exposition that feature findings from its multiple myeloma and sickle cell disease research networks. “The ASH RC has brought the multiple myeloma and sickle cell disease communities together to generate real-world evidence for res